Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Melanoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Insulinoma 1Hodgkin Disease 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gliosarcoma 1Glioma, Subependymal 1Glioblastoma 1Gastrinoma 1

Interventions

exemestane 2Letrozole 2seviteronel 1sargramostim 1ribociclib 1methyl N-acetylsibirosaminide 1elacestrant 1Trastuzumab 1Tamoxifen 1Suspensions 1Receptor Protein-Tyrosine Kinases 1Presenilin-1 1Pemetrexed 1Leuprolide 1Injections 1HER2 peptide (369-377) 1Granulocyte-Macrophage Colony-Stimulating Factor 1Goserelin 1Fentanyl 1Anastrozole 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms, Male × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT00006370 2013-05-01

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Novartis

Phase 2 Completed
275 enrolled
BreastThoracic

Breast Neoplasms, Lung Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡